DNAPrint Inks Deal With Pharsight
SARASOTA, Fla.--(BUSINESS WIRE)--Aug. 24, 2001--DNAPrint genomics, Inc. (OTCBB:DNAP) announced today that it has entered into a contract with Pharsight Corp. (Nasdaq:PHST) of Mountain View, CA, which will allow DNAPrint to accelerate its pharmacogenomics research and product development. Under the terms of the agreement, Pharsight will supply DNAPrint with clinically phenotyped specimens from patients taking a variety of variably efficacious medications. Additional terms of the agreement were not disclosed.
The relationship with Pharsight will increase DNAPrint's specimen databank by about 10%, and lays the foundation for other more extensive collaborative efforts between the companies in the future. DNAPrint presently collects specimens using its' network of Florida physicians. The Pharshight partnership compliments these efforts and helps the company meet its' goal of having several thousand specimens in its' multi-drug consent databank by year's end.
The specimen databank DNAPrint is compiling is unique in the pharmacogenomics industry. Rather than collect specimens and clinical data relevant for a particular drug project, DNAPrint's collection efforts are carried out to target patient types. Each specimen in DNAPrint's databank has multi-drug consent, and is clinically noted with the patient's drug, clinical and biographical data, spanning on average, 7 years of the their medical history. The average specimen in the databank is annotated with numerous medication -- clinical end point test result combinations, called "events", and a majority of the specimens have multiple events for the same drug. It is this depth and breadth that makes DNAPrint's databank unique, and well suited for the companies effort to "genotype every patient at every pharmaco-relevant marker" for the execution of numerous, simultaneous pharmacogenomics projects. This will allow DNAPrint to be able to develop genomics patient-drug classification products for a fraction of the cost incurred by others in the industry.
About Pharsight:
Pharsight is a science-based company with a mission to enable fundamental improvements in the clinical development of therapeutic products. The company's solutions help pharmaceutical and biotechnology companies make confident decisions in dealing with complex issues of drug development and product portfolio management.
About DNAPrint genomics, Inc.
DNAPrint genomics Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. The company is developing personalized medicine technologies and kits to help physicians match patients with drugs best suited for their genetic architecture. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit dnaprint.com.
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
CONTACT: DNAPrint genomics, Inc., Sarasota
For Scientific inquiries:
Tony Frudakis, Ph.D., 941/366-3400
or
Other inquiries
Tim Wilkins, 941/923-1949 |
